| Species |
Human |
| Protein Construction |
Interferon omega-1 (Leu22-Ser195)_x000D_
Accession # P05000 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
21.25 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human Interferon omega-1, a type I IFN, also known as IFN-ω1 or IFNW1, it contains a potential N-glycosylation site like human IFN-β. IFN-ω1 binds to the interferon alpha/beta receptor but not to the interferon gamma receptor. All IFN-ω genes analysed to date are devoid of introns. IFN-ω1 has been shown to be well-tolerated in man and to induce reductions of hepatitis C virus RNA levels in a series of human clinical trials. |
| Synonyms |
Interferon alpha-II-1; IFNW1; IFN-ω1; IFN-omega-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
